Skip to content

Cognitive Function Analysis and qEEG Study in Long COVID-19 Syndrome Patients

Cognitive Function Analysis and qEEG Study in Long COVID-19 Syndrome Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05670418
Enrollment
45
Registered
2023-01-04
Start date
2022-10-01
Completion date
2023-12-30
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long COVID-19 Syndrome

Keywords

Long COVID-19 Syndrome, COVID-19, Quantitative electroencephalography, Case-control study

Brief summary

Over than 30% individuals with COVID-19, including the asymptomatic ones, and around 80% of patients hospitalized with COVID-19 may experience post-COVID sequelae, which is commonly referred to as Long COVID Syndrome. This condition has ties to decreased cognitive function and may lead to neuropsychiatric disorders but still need to be studied further. Using a cross-sectional design, this study will analyze the relationship between cognitive function and neuropsychiatric disorders with brain wave activity in Long COVID patients. The investigators conducted assessments utilizing the quantitative electroencephalogram (qEEG) measurement method and interviews using instruments such as the MOCA questionnaire and Self Rating Questionnaire (SRQ). With this qEEG examination, the investigators hoped that there will be an imbalance/abnormality of brain wave activity that arises related to impaired cognitive function.

Detailed description

This study is aimed to analyze the cognitive function and neuropsychiatry disorders with brain wave activity using qEEG that occurs after COVID/Long Covid Syndrome. The whole procedure will run for approximately 12 weeks based on the long COVID range. The determinants of long COVID patients include: never been vaccinated, old age, comorbid, female population, and hospitalized patients. The total number of subjects with the post-COVID syndrome in the proportion test is 30 subjects. The measuring instruments used to measure the decline in cognitive function are the MOCA questionnaire and Self Rating Questionnaire (SRQ). The target population is post-COVID-19 patients with Long COVID Syndrome. The accessible population is post-COVID-19 patients who have been treated at RSCM Kiara and have regular checkups at the RSCM polyclinic with Long COVID Syndrome for 12 weeks or more. The control population is post-COVID-19 patients who managed to recover without symptoms. The Long COVID Syndrome patients who meet the inclusion criteria and have signed the consent.

Interventions

DEVICEQuantitative Electroencephalography

Each qEEG examination of one person lasted about 20 minutes and included two stages: the first-recording of brain waves with eyes closed (5 min), the other with eyes open (5 min)

Sponsors

Indonesia University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Post-COVID-19 patients with Long COVID-19 Syndrome 2. Over 18 years old 3. Willing to participate in the research 4. Completed the Montreal Cognitive Assessment (MoCA) and Self Rating Questionnaire (SRQ)

Exclusion criteria

1\. Patients with neuropsychiatric disorders before being infected with COVID-19

Design outcomes

Primary

MeasureTime frameDescription
Cognitive FunctionThrough study completion, an average of 1 yearCognitive Function will be assessed using the qEEG, with an abnormality of brain wave activity, it indicates impairment of cognitive function

Secondary

MeasureTime frameDescription
Cognitive quality Assessed by MOCAThrough study completion, an average of 1 yearSevere score: ≤10 Moderate score: 10-17 Mild score: 18-25 Normal score: 26-30
Self Rating Questionnaire (SRQ)Through study completion, an average of 1 yearLowest score: 0 Highest score: 20. Higher score indicates better health status.

Countries

Indonesia

Contacts

Primary ContactYetty Ramli, MD
yettyramli@gmail.com+62811163843
Backup ContactDyah Tunjungsari, MD
penelitian.neuroui@gmail.com+628119884224

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026